Maylan gets favourable ruling on one more patent of Copaxone
The company, which is Natco Pharma's marketing partner, hopes to translate this potential para-4 filing into a product launch after clearing legal hurdles
BS Reporter |
Last Updated at September 2, 2016 19:32 IST
Natco Pharma Limited on Friday announced that the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan in its new trial proceedings over the claims of a third patent of multiple scleroses drug Copaxone 40 mg/ml and found the claims unpatentable.
On August 24, the US Patent Office ruled in favour of Mylan on claims of two patents of blockbuster drug Copaxone.
The company hopes to translate this potential para-4 filing into the launch after clearing the legal hurdles one by one. Israeli generic pharmaceutical major Teva owns the drug.
It had launched the long working Copaxone 40 mg/ml injection closer to the expiry of Copaxone 20 mg/ml, which already have generic equivalents available in the US market.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard
First Published: Fri, September 02 2016. 18:26 IST